Age: 40.0
Sex: F
Vaccine: COVID19
Symptoms: COVID-19, SARS-CoV-2 test
Clinical narrative: COVID-19; This spontaneous case was reported by a consumer and describes the occurrence of COVID-19 (COVID-19) in a 40-year-old female patient who received mRNA-1273 (Moderna COVID-19 Vaccine) for COVID-19 vaccination.     The patient's past medical history included Astrocytoma in 2019 and Astrocytoma resection (no chemo or radiation) in 2019.   On 24-Mar-2021, the patient received first dose of mRNA-1273 (Moderna COVID-19 Vaccine) (unknown route) 1 dosage form. On 17-Apr-2021, received second dose of mRNA-1273 (Moderna COVID-19 Vaccine) (unknown route) dosage was changed to 1 dosage form. On 02-Dec-2021, received third dose of mRNA-1273 (Moderna COVID-19 Vaccine) (unknown route) dosage was changed to 1 dosage form. On 17-May-2022,  after starting mRNA-1273 (Moderna COVID-19 Vaccine), the patient experienced COVID-19 (COVID-19). The patient was treated with NIRMATRELVIR, RITONAVIR (PAXLOVID) from 18-May-2022 to 22-May-2022 for COVID-19 treatment, at a dose of all doses taken on schedule (5 days with dose in morning and evening). At the time of the report, COVID-19 (COVID-19) had not resolved.      DIAGNOSTIC RESULTS (normal ranges are provided in parenthesis if available): On 17-May-2022, SARS-CoV-2 test: positive (Positive) Tested positive on 17 May at home. On 18-May-2022, SARS-CoV-2 test: positive (Positive) positive test again at dr office on 18 May. On 25-May-2022, SARS-CoV-2 test: negative (Negative) tested negative on 25 May. On 30-May-2022, SARS-CoV-2 test: positive (Positive) tested positive again on 30 may with stuffy nose and fatigue, shortness of breath.         Patient had no relevant past drug allergy. No concomitant product reported by reporter. Patient stated experiencing COVID-19 symptoms on 29 May 2022 include stuffy nose, fatigue and shortness of breath. device date 30 May 2022.  Company Comment: This is a spontaneous case concerning a 40-year-old female patient with no relevant medical history, who experienced the unexpected, non-serious, adverse event of special interest, COVID-19 which occurred approximately 2 months after receiving the first dose of mRNA-1273 Vaccine. As reported, the patient tested positive 2 months after the first dose. The next day started on Paxlovid treatment for 5 days. Subsequent tests were negative however, 11 days from the start of treatment, patient began to exhibit symptoms then tested positive again the next day with stuffy nose, dyspnea, and fatigue. No other other clinical or treatment details were given. The reported outcome of the event has not resolved. The benefit-risk relationship of mRNA-1273 Vaccine is not affected by this report.   This case was linked to MOD-2022-580387 (Patient Link).; Sender's Comments: This is a spontaneous case concerning a 40-year-old female patient with no relevant medical history, who experienced the unexpected, non-serious, adverse event of special interest, COVID-19 which occurred approximately 2 months after receiving the first dose of mRNA-1273 Vaccine. As reported, the patient tested positive 2 months after the first dose. The next day started on Paxlovid treatment for 5 days. Subsequent tests were negative however, 11 days from the start of treatment, patient began to exhibit symptoms then tested positive again the next day with stuffy nose, dyspnea, and fatigue. No other other clinical or treatment details were given. The reported outcome of the event has not resolved. The benefit-risk relationship of mRNA-1273 Vaccine is not affected by this report.